Diagnose on
DAYZERO

Revolutionizing infectious disease diagnosis and treatment with genomic sequencing and machine learning to solve antibiotic resistance.

Featured NEWS

Day Zero Diagnostics Welcomes Healthcare Business Leader Gail Marcus to its Board
Day Zero Diagnostics Inc. announced that Gail Marcus has joined the company’s Board of Directors as an independent director.
Read More
Day Zero Diagnostics Awarded $8.2 Million in Additional CARB-X Funding To Support Ongoing Development of its Infectious Disease Rapid Diagnostic
DZD Will Continue Clinical Validation and Product Engineering of its Novel Technology Designed to Reduce Time to Diagnosis from Days to Hours
Read More
Day Zero Diagnostics Welcomes Molecular Diagnostics Experts to its Advisory Board
Dr. Amy Mathers and Rob Crisp Bring Extensive Academic and Industry Experience
Read More

Public Health Crisis

Antibiotic resistance is an ongoing crisis that causes at least 700,000 global deaths annually. By 2050, this figure is expected to grow to 10 million. Patients can die of a severe infection like sepsis within hours, but current diagnostics for antibiotic resistance can take 2-5 days or never return a result at all. Physicians are left to treat using trial and error approaches based on limited information – the exact opposite of precision medicine.

Learn More

What We Do

DZD is developing rapid, whole genome sequencing-based diagnostics to modernize infectious disease diagnosis and treatment.

We are harnessing the power of the genome to build technologies that both precisely identify the species and provide the comprehensive antibiotic susceptibility / resistance profile of a bacterial infection within hours, rather than days, so that patients can be treated with the most effective antibiotic quickly. Faster treatment with the right antibiotic saves lives and reduces the cost and complications associated with extended episodes of care.

View Our Work

Rapid Response Partner

DZD is also developing technologies to help control HAIs (healthcare-associated infections), where antibiotic resistant organisms can be especially dangerous. Our rapid turnaround epiXact® service uses whole genome sequencing to provide infection control professionals with precise information on pathogen relatedness in less than 2 days, so they can make the right intervention decisions early and confidently.

Learn More